$APVO (Aptevo Therapeutics) — 8-K: Aptevo preclinical data show APVO451, APVO452, APVO711 overcome tumor immune suppression

Aptevo presented preclinical data at SITC 2026 showing APVO451 and APVO452 drove tumor-cell killing and T-cell activation under immunosuppressive conditions, while APVO711 both activated immune cells and blocked a signal that weakens their response. The molecules combine CD40 activation with T-cell engagement in a single antibody-like construct. The findings support continued development of the company's next-generation multispecific platform for difficult-to-treat solid tumors.

Aptevo presented preclinical data at SITC 2026 showing APVO451 and APVO452 drove tumor-cell killing and T-cell activation under immunosuppressive conditions, while APVO711 both activated immune cells